Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.

A previous study showed that miR-221/222 can regulate cell apoptosis. p53 is a well known tumor suppressor which can influence the chemosensitivity of glioma cells. However, the effect of miR-221/222 in gliomas with different p53 status is unknown. Here, we demostrate that knockdown of miR-221/222 increases apoptosis in human gliomas of different p53 types (U251 cells, p53 mutant-type; LN308 cells, p53 null-type; and U87 cells, p53 wild-type). Furthermore, the effect of miR-221/22 caused no change of p53 expression in the glioma cells studied. In addition, when a specific siRNA against p53 was employed in U87 cells, no attenuation of apoptosis was found after knockdown of miR-221/222. Importantly, we found that As-miR-221/222-treated cells increased expression of Bax, cytochrome c, Apaf-1 and cleaved-caspase-3. Our results showed that low expression of miR-221/222 sensitized glioma cells to temozolomide (TMZ); in addition, ectopic expression of PUMA by pcDNA-PUMA had a similar effect. Taken together, our study indicates that downregulated miR-221/222 can sensitize glioma cells to TMZ by regulating apoptosis independently of p53 status.

[1]  J. Cairncross,et al.  Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma , 2011, Journal of Neuro-Oncology.

[2]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[3]  C. Kang,et al.  miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. , 2010, International journal of oncology.

[4]  Mei Mei,et al.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status , 2010, Laboratory Investigation.

[5]  C. Berking,et al.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. , 2009, The Journal of clinical investigation.

[6]  Hao Jiang,et al.  Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. , 2009, International journal of oncology.

[7]  Andrea Ventura,et al.  MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.

[8]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[9]  Zhenbao Yu,et al.  Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. , 2008, Carcinogenesis.

[10]  S. K. Zaidi,et al.  MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. , 2008, Cancer research.

[11]  C. Croce,et al.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.

[12]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[13]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[15]  S. Kyo,et al.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. , 2005, Human gene therapy.

[16]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[17]  I. Nakano,et al.  Cancer stem cells in pediatric brain tumors. , 2004, Current stem cell research & therapy.

[18]  Jian Yu,et al.  No PUMA, no death: implications for p53-dependent apoptosis. , 2003, Cancer cell.

[19]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[20]  S. Green,et al.  GliaSite Brachytherapy for Treatment of Recurrent Malignant Gliomas: A Retrospective Multi-institutional Analysis , 2006, Neurosurgery.

[21]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .